Sales of Cimzia were ¥3.2 billion in fiscal 2013. Cimzia, a  rheumatoid arthritis treatment in-licensed from UCB  Pharma, S.A. of Belgium, was launched in March 2013 in  Japan. Astellas is co-promoting Cimzia with UCB Japan  Co., Ltd. Sales of Geninax decreased 4.5% to ¥11.7 billion in line  with a contraction in the Japanese market for oral quino- lone antibiotics and other factors. In fiscal 2013, the market  contracted 3.5% year on year to approximately ¥59.0 bil- lion. Geninax’s share was around 22% (on a value basis),  making it the second-largest seller in the market. In Octo- ber 2013, Astellas began selling small Geninax tablets that  are easier for patients to take. Astellas will continue work- ing hard to achieve further market penetration through  co-promotion with Taisho Toyama Pharmaceutical Co., Ltd. Sales of Bonoteo rose by a strong 32.4% year on year to  ¥14.1 billion. The release in September 2011 of a 50 mg  tablet to be taken once every four weeks contributed sig- nificantly to this increase in sales. Sales of Bonoteo Tablets  50 mg amounted to ¥13.1 billion. In fiscal 2013, the Japa- nese market for the treatment of osteoporosis shrank 1.2%  to around ¥79.0 billion. Bonoteo’s share in this market  grew steadily to around 20% (on a value basis). Astellas will  continue emphasizing patient convenience as well as the  bone fracture prevention effect of Bonoteo 50 mg tablets  while aiming to further boost its share in this market. In June 2014, an application was filed for an additional  indication that will make it possible to administer Cimzia to  RA patients without previous treatment with anti-RA drugs. * Refers to proactive participation by patients in deciding on a treatment plan, and  receiving treatment according to the decision. involved in the onset and exacerbation of inflammatory  diseases such as rheumatoid arthritis (RA), and selectively  inhibits its effects. Cimzia is supplied in the form of a pre- filled syringe to facilitate self-administration by RA patients  trained by their healthcare professionals. In addition to  offering efficacy and safety, the Cimzia is designed to facili- tate usage by patients themselves. Cimzia is expected to  play an important role in improving the symptoms of rheu- matoid arthritis patients, as well as their quality of life and  adherence.* Following the approval of long-term prescrip- tions from March 2014, Astellas will work hard to achieve  further market penetration of Cimzia. Suglat is a selective SGLT2 (Sodium-Glucose Co-Transporter  2) inhibitor discovered through a research collaboration  with Kotobuki Pharmaceutical Co., Ltd. (“Kotobuki”) and  jointly developed by Astellas and Kotobuki. In January  2014, it became the first SGLT2 inhibitor to be approved  as a treatment for type 2 diabetes in Japan, and was  launched in April 2014. SGLTs are membrane proteins that exist on the cell  surface and transfer glucose into cells. SGLT2 is one sub- type of SGLTs and plays a key role in the reuptake of glu- cose in the proximal tubule of the kidneys. Suglat reduces  blood glucose levels by inhibiting the reuptake of glucose  by selectively inhibiting SGLT2. In fiscal 2013, the market for oral hypoglycemic agents  in Japan was valued at around ¥342.0 billion. Astellas will  provide a new type 2 diabetes treatment option through  the launch of Suglat, an oral type 2 diabetes treatment  based on a novel mechanism of action. In the process,  Astellas will continue working hard to achieve further  market penetration of Gonax along with XTANDI, which  was launched in May 2014. Sales of Gonax were ¥2.5 billion in fiscal 2013. Gonax is a  gonadotrophin-releasing hormone (GnRH)-receptor blocker  with a subcutaneously injectable formulation in-licensed  from Ferring Pharmaceuticals. Gonax was launched in  Japan in October 2012. GnRH is a hormone produced by  the hypothalamus in the brain and is involved in the pro- duction of the male hormone testosterone through binding  to the GnRH-receptors in the pituitary gland. Although  testosterone is an important hormone that plays a central  role in the maintenance of male function, it also stimulates  prostate cancer to grow and spread, which often aggravates  symptoms in prostate cancer patients. Gonax competitively  inhibits the binding of GnRH to the GnRH-receptors, con- trolling the growth of prostate cancer by suppressing the  testosterone production. Suglat (Type 2 diabetes treatment (selective SGLT2 inhibitor)) Gonax (Prostate cancer treatment) Bonoteo (Treatment for osteoporosis) Cimzia has a high affinity for TNF-alpha, which is  Cimzia (rheumatoid arthritis treatment) Geninax (Oral quinolone antibiotic) Financial Section Annual Report 2014 _  Astellas Pharma Inc.  91